An interventional study of Deep Brain Stimulation in Obsessive-Compulsive Disorder, sponsored by University Hospital, Grenoble. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Obsessive-Compulsive Disorder with a site in France — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · France.
Among the 20 studies in Obsessive-Compulsive Disorder with a site in France, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 with no phase, and was the 9th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →5 of the 20 studies in Obsessive-Compulsive Disorder with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier St Anne · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Centre Hospitalier Henri Laborit · Sites in France
Ages 18–70
Centre Hospitalier Henri Laborit · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 2005; this study’s year is marked. 3 started in 2016.
This study's planned enrollment of 60 is above the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 45 across the 18 interventional studies, 7 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 3 studies filed under Obsessive-Compulsive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Obsessive-Compulsive Disorder with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06017713Centre Hospitalier Henri LaborittDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder | 2027-04 |
| NCT04934007Centre Hospitalier Henri LaboritBilateral Lateral OFC rTMS in Obsessive Compulsive Disorder | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Obsessive-Compulsive Disorder with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Obsessive-Compulsive Disorder (OCD) is among the most disabling psychiatric disorders as more than 40% of patients are resistant to the standard pharmacological and psychotherapy approaches and about 10% show severe disability and require institutionalization. These resistant patients may benefit from new surgical therapeutic approaches such as Deep Brain Stimulation (DBS) using high frequency stimulation of specific cerebral regions to modulate neural networks. Although promising, these results need nevertheless to be replicated and confirmed within a larger cohort of patients and considering a different main objective, instead of clinical improvement only. Indeed, despite a positive treatment response, adaptive functioning and quality of life may continue to be negatively impacted in OCD. Thus beyond symptom reduction, health-related quality of life (QoL) represents a more important objective of a treatment, as it includes both the individual's functional status and the individual's subjective perception of the impact of the illness on the patient's life. STN DBS induces significant clinical improvement, which may not be proportional to the QoL gain. Consequently, QoL appears to be a better outcome to target in the coming studies than clinical improvement alone. THe investigators thus propose a prospective study assessing the QoL changes of resistant OCD patients under STN DBS+BMT versus Best Medical Treatment (BMT) at 12 months, in order to assess the DBS induced gain in QoL in BMT-managed patients versus BMT alone.
The study will focus on an innovative therapeutic strategy (DBS) and on an original objective, quality of life, which is considered to better reflect the impact of a therapeutic strategy. Moreover, the study will help to define the predictive biomarkers /biosignatures of response to STN DBS in OCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DBS surgical procedure scheduled and realized
Device: Deep Brain Stimulation
medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
surgical procedure
Also known as: DBS
Assessment of the impact of DBS+BMT versus BMT alone on a measure of Quality of life in resistant OCD patients at 1-year follow-up
QOL assessment : scores at SF36
Time frame: 1 year
Psychiatric assessment n°1
clinical profile defined by score at YBOCS -Yale Brown Obsessive Compulsive Scale
Time frame: 1 year
Psychiatric assessment n°2
clinical profile defined by score at DYBOCS- Dimensional Yale Brown Obsessive Compulsive Scale
Time frame: 1 year
Psychiatric assessment n°3
clinical profile defined by score at YMRS (Young Mania Rating Scale)
Time frame: 1 year
Psychiatric assessment n°4
clinical profile defined by score at HAMA (Hamilton Rating Scale for Anxiety)
Time frame: 1 year
Psychiatric assessment n°5
clinical profile defined by score at STAI (State-Trait Anxiety Inventory)
Time frame: 1 year
Psychiatric assessment n°6
clinical profile defined by score at UPPS-P Impulsive Behavior Scale
Time frame: 1 year
Psychiatric assessment n°7
clinical profile defined by score at Clinical Global Impression (Severity of OCD)
Time frame: 1 year
Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°1
Functioning scores : GAF (Global assessment functioning scale)
Time frame: 1 year
Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°2
Functioning scores : WHODAS 2.0
Time frame: 1 year
side effects
Number of patients with side effects related to medical treatment, surgery and to stimulation
Time frame: 1 year
Psychiatric markers n°1
scores at Big Five Inventory
Time frame: 1 year
Psychiatric markers n°2
scores at BABS (BROWN ASSESSMENT OF BELIEFS SCALE)
Time frame: 1 year
Neurological markers n°3
score at UPDRS (Unified Parkinson's Disease Rating Scale)
Time frame: 1 year
Neuropsychological markers n°4
Score at OBQ-44 (Obsessive Beliefs Questionnaire)
Time frame: 1 year
Neuropsychological markers n°5
Score at MCQ (Metacognitions questionnaires)
Time frame: 1 year
Neuropsychological markers n°6
Score at URICA (University Rhode Island Change Assessment Scale)
Time frame: 1 year
Neuropsychological markers
Score at Addenbrooke Cognitive Examination (ACE) battery
Time frame: 1 year
Per-op electrophysiological mapping of the STN activity n°1
electrophysiological parameters at rest and during OCD provocative tests
Time frame: 1 year
Per-op electrophysiological mapping of the STN activity n°2
electrophysiological parameters at rest and during OCD uncertainty test
Time frame: 1 year
Per-op electrophysiological mapping of the STN activity n°3
electrophysiological parameters at rest and during OCD emotional test
Time frame: 1 year
Per-op electrophysiological mapping of the STN activity n°4
electrophysiological parameters at rest and during OCD cognitive and motor test
Time frame: 1 year
Assessment of the suicidal risk under DBS+BMT vs BMT in resistant OCD
Measure of suicidal risk with MADRS scale
Time frame: 1 year
Not enrolling at this site.
Plan to share: No
Started Sep 2016 (actual). Primary completion is estimated for Jul 2026, 118 months after the start.
Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 118 months is above that.
Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
University Hospital, Grenoble →